Skip to main content
Commercial newswire·

Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight

A diversified late-stage pipeline encompassing endothelin receptor antagonists, aldosterone synthase inhibitors such as lorundrostat, APOL1 inhibitors including MZE829, and cell therapy approaches such as rilparencel is poised to intensify competition, with each modality addressing...

Short extract only — this publisher licenses its text. Read the full release at the source.

More from Commercial newswire

The rest of this wire is for subscribers

Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.

7 days, no card required.

Read releases like this the second they cross the wire.

1,400+ feedslive on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.

Start the free trial →

Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.

PPN Source →
Shared via PPN World — real-time press release intelligence.